key: cord-0764020-rqx42uvt
authors: Telford, Erica; Ortega-Perez, Inmaculada; Mellon, Guillaume; Lacarra, Boris; Adjadj, Elisabeth; Madelaine, Claire; D’Ortenzio, Eric; Yazdanpanah, Yazdan
title: Chronicles of a pandemic: how France coordinated the scientific research response to COVID-19
date: 2021-08-28
journal: Infect Dis Now
DOI: 10.1016/j.idnow.2021.08.003
sha: d1cca28f6c470834c87db8f49b94deaf3a36cc1b
doc_id: 764020
cord_uid: rqx42uvt

nan

J o u r n a l P r e -p r o o f reported by France on January 24, 2020 [1] . The first clusters emerged in the country as early as February 2020, substantiating active virus circulation. The extremely rapid dissemination of cases led French authorities to impose a national stringent lockdown on March 17, alongside many other countries. J o u r n a l P r e -p r o o f epidemiology, disease control and prevention, and ethical and social sciences, for a total amount of €32.2M [3] . The ANR further expanded its commitment by including COVID-19 as a research priority in its 2021 funding plan. The ANRS opened a call for projects dedicated to low-and middle-income countries (LMICs). The Fondation de France, the Public Hospitals of Paris (AP-HP) and the Institut Pasteur coordinated efforts to support health care workers and hospital first response, and to fund research projects on COVID-19 detection, treatment and prevention through a community-based solidarity initiative "All united against the virus", launched in March 2020. National and interregional PHRC programs funded the implementation of 58 clinical studies. Overall, nearly 100 research projects on pharmaceutical treatments and more than 300 on non-pharmaceutical interventions were launched within the first six months of the pandemic, facilitated by a pivotal shortening of authorization delays through fast-track procedures. Pharmaceutical treatments tested included several classes of repositioned antivirals, anti-inflammatory drugs to contrast the excessive inflammatory response and anti-coagulants to prevent thrombotic events observed in COVID-19 patients.

Projects on non-pharmaceutical interventions ranged from the clinical context, such as characterization of disease progression and biomarkers, and patient management, to epidemiologic and transmission studies, investigation of mental health status of different populations, and diagnostic tool development.

Although simultaneous opening of a multitude of therapeutic clinical research projects by several institutions illustrates the extraordinary mobilization of researchers in the fight against the pandemic, it hampered successful implementation and patient recruitment strategies. The crisis response has been extensive but scattered on various fronts, suffering from an important lack of coordination between funding agencies and between researchers and decision-makers, and from the lack of readiness in the research community to mobilize funding and human resources. The situation assessment documents released in June and July 2020 consequently proposed actions to implement and consolidate a coordinated crisis response in the short and long term. For instance, the Rossignol report Analysis of the first 135,000 questionnaires and 12,000 serological samples determined the adult population in metropolitan France that had been exposed to the virus (4.5%) and its socio-demographic characteristics [9] .

In parallel with such epidemiological studies, interdisciplinary research on public health urged to be accelerated, notably promoting the cooperation between epidemiology and social sciences to understand the social dimensions of infection risks and the effects of containment measures on physical and mental health. To this aim, the SAPRIS study, a nationwide survey coordinated by Inserm and Santé publique France, was launched in April 2020 involving 200,000 participants from four pre-existing national general population cohorts. The main questions focused on COVID-19 symptoms, consultations for other pathologies, perception of risk, and effects of preventive measures on daily life, among others. These data were integrated with serological testing of participants to evaluate national seroprevalence and its correlation with socio-demographic factors. EpiCov and SAPRIS data were further exploited by the COVIDSM study, sponsored by Inserm in April 2021, and aimed at evaluating the impact of the health crisis on the population's mental health. Lastly, several mathematical modelling studies have been implemented since the early days of the pandemic, exploiting data such as disease prevalence, infection rates, or mobile phone data tracking population behaviors [10, 11] . This approach allowed, among others, to characterize and anticipate the impact of public health interventions, from lockdown and school closure to mass screening and vaccination strategies, on disease control or epidemic rebounds [12, 13] . The public health studies described so far, along with many others promptly implemented, helped define control and mitigation strategies. Hence, recommendations were issued by national public health authorities to contain infections while preserving individual health.

While public health notions were developed, research on the natural history of the disease was crucially important to manage COVID-19 patients. A representative instance is the prompt establishment of the French-Covid national cohort of COVID-19 patients admitted to hospital general wards or intensive care units. French-Covid, coordinated by Inserm, exploited clinical, virological, immunological, genetic, serologic, and transcriptomic patient data to better understand clinical manifestations of the disease, particularly in its severe forms.

Studies based on the French-Covid cohort allowed to estimate viral dynamics, evolution of patient's clinical status, and mortality of the disease. Moreover, several independent studies relied on data issued from the French-Covid cohort. These helped characterizing genetic and immunologic factors associated with severe COVID-19 presentations (notably linked to type I interferon defects), evaluating the impact of treatments such as corticosteroids or hypertensive drugs on progression of the disease, or identifying disease biomarkers [14, 15] .

To characterize milder COVID-19 forms not requiring hospitalization, support was provided by COVIDOM, an on-line platform for distance monitoring of patients with a suspected or diagnosed SARS-CoV-2 infection, developed by the AP-HP and Nouveal e-santé. Based on COVIDOM data, a study issued by a collaboration between the AP-HP, Inserm and French universities followed disease progression of 43,000 COVID-19 outpatients, describing clinical worsening as rare [16] . More recently, Covid-A was set up, a prospective observational study to evaluate clinical and virological evolution of symptomatic outpatients older than 8 years with a suspected SARS-CoV-2 infection who referred to a general practitioner or pediatrician.

As the natural history of the disease was unraveled over time, evidence showed that COVID-19 can induce long-term consequences on the patient's physical and mental health, a condition defined as post-acute COVID-19 syndrome (PACS). To study PACS, French-Covid followed the clinical situation of cohort patients after hospital discharge, demonstrating that after 3 to 6 months, 60% of a group of 1,137 patients had at least one persisting symptom [17] . Among several other studies on PACS, the COPER and DisCOVID projects were funded by MERSI and the MSS. The first aimed to characterize persisting symptoms after resolution of a SARS-CoV-2 infection, while the latter, sponsored by the AP-HP, evaluated disability levels and profiles in the mid-and long-term after COVID-19-related hospitalization. Complementarily, researchers from Paris University, AP-HP and Inserm, in the context of the ComPaRe cohort, developed the first scientific tool to measure in a standardized manner the long-term symptoms and impact of COVID-19 [18] . [19, 20] . Subsequently, Inserm is now coordinating the new European

Response. This structure includes Solid-Act, a platform for adaptative trials that is currently evaluating the efficacy and tolerance of the anti-inflammatory baricitinib for management of severe COVID-19 patients (Bari-SolidAct study), and DisCoVeRy that is testing AstraZeneca's This bibliometric analysis, although reflecting the state of the art at a given moment and evolving over time, shows that the French scientific community maintained a constant participation in research during the international COVID-19 crisis, sustaining a steady research level of publication and being ranked among the top two countries for publication in high impact factor journals.

To conclude, the unprecedented COVID-19 crisis required an unparalleled collaborative multi-disciplinary effort, which France responded to. The COVID-19 pandemic challenged us as nations and as scientific communities, but valuable lessons on coordinated efforts and targeted research funding have been learnt on the way, which will change scientific research for years to come. However, it must be remarked that many of the described crucial responses and actions relied on existing networks and research platforms that, fueled by sudden funding, allowed an otherwise unattainable response. A crucial take-home message from the last 18 months must be that proper development of research infrastructure, organized management of financial means and coordination of a common response of scientists, health professionals, regulating agencies and political actors must be the cornerstone in times of preparedness as much as it has been in times of crisis.

Erica Telford, Guillaume Mellon, and Inmaculada Ortega-Perez conceived and designed the study, drafted the manuscript, and critically revised and reviewed the work. Boris Lacarra conceived and designed the study, and critically revised and reviewed the manuscript.

Elisabeth Adjadj performed bibliometric data analysis for the work, and critically revised the manuscript. Claire Madelaine and Eric D'Ortenzio critically revised and reviewed the manuscript. Yazdan Yazdanpanah conceived and designed the study, and critically revised and reviewed the manuscript for final approval.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. 

First cases of coronavirus disease 2019 (COVID-19) in France: Surveillance, investigations and control measures

Mobilisation de l'Agence nationale de la recherche pour la recherche COVID-19 : 234 projets de recherche financés pour un montant global de 32,2 millions d ' euros

Mission essais cliniques en contexte épidémique

Proportion de professionnels de santé infectés après exposition professionnelle avérée au SARS-CoV-2 : résultats préliminaires de la cohorte CoV-CONTACT

Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study

Etude des facteurs sociodémographiques, comportements et pratiques associés à l'infection par le SARS-CoV-2 (ComCor)

Caisse Nationale d'Assurance Maladie;IPSOS

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

En mai 2020, 4,5 % de la population en France métropolitaine a développé des anticorps contre le SARS-CoV-2. Premiers résultats de l'enquête nationale EpiCov. Etudes & Résultats -Direction de la recherche, des études

Estimating the burden of SARS-CoV-2 in France

Evaluating the effect of demographic factors, socioeconomic factors, and risk aversion on mobility during the COVID-19 epidemic in France under lockdown: a population-based study

Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France

Modelling safe protocols for reopening schools during the COVID-19 pandemic in France

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

Clinical characteristics and factors associated with hospital admission or death in 43 103 adult outpatients with coronavirus disease 2019 managed with the Covidom telesurveillance solution: a prospective cohort study

Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort

Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients' lived experience

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Remdesivir for the treatment of hospitalised patients with COVID-19 (DisCoVeRy): a randomised, controlled, open-label trial

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, doseranging study

Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models

A French cohort for assessing COVID-19 vaccine responses in specific populations